Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Arena Pharmaceuticals Inc (NASDAQ:ARNA)

1.40
Delayed Data
As of Jan 23
 +0.03 / +2.19%
Today’s Change
1.32
Today|||52-Week Range
2.16
-1.41%
Year-to-Date
Why Arena Pharmaceuticals Stock Sank in 2016
Jan 13 / MotleyFool.com - Paid Partner Content
VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan 11 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close1.37
Today’s open1.37
Day’s range1.35 - 1.42
Volume1,392,100
Average volume (3 months)1,752,245
Market cap$333.3M
Dividend yield--
Data as of 01/23/2017

Growth & Valuation

Earnings growth (last year)-60.71%
Earnings growth (this year)+26.34%
Earnings growth (next 5 years)-45.30%
Revenue growth (last year)+3.67%
P/E ratioNM
Price/Sales11.93
Price/Book6.21

Competitors

 Today’s
change
Today’s
% change
SVASinovac Biotech Ltd0.000.00%
RARXRa Pharmaceuticals I...+1.02+6.91%
ADXSAdvaxis Inc-0.12-1.46%
NLNKNewLink Genetics Cor...-0.27-2.38%
Data as of 01/23/2017

Financials

Next reporting dateMarch 6, 2017
EPS forecast (this quarter)-$0.08
Annual revenue (last year)$38.3M
Annual profit (last year)-$108.0M
Net profit margin-281.74%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Amit D. Munshi
SVP-Operations &
Head-Global Regulatory Affairs
Craig M. Audet
Corporate headquarters
San Diego, California

Forecasts


Search for Jobs